" class="no-js "lang="en-US"> Stanley C. Erck - Medtech Alert
Sunday, October 06, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Stanley C. Erck

Stanley C. Erck

About Stanley C. Erck

Experienced CEO in biotechnology industry. Have developed multiple products from early start-up through Phase2/3 clinical trials in infectious disease, vaccines, with multiple rounds of financing from Series A through 2 IPO’s and acquisitions.

Specialties: infectious disease, autoimmune disease, genetic disease, immunology

Related Story

COVID-19

 Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom | Pharmtech Focus

Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom

September 28 2022

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for […]

COVID-19

 Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes | Pharmtech Focus

Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes

July 20 2022

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for […]

COVID-19

 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

July 15 2022

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for […]

COVID-19

 U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine | Pharmtech Focus

U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

July 12 2022

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]

COVID-19

 Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over | Pharmtech Focus

Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

June 14 2022

Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]

COVID-19

 Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom | Pharmtech Focus

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

October 27 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious […]

Diseases

 Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases | Pharmtech Focus

Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases

September 24 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]

COVID-19

 Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 Million Doses of COVID-19 Vaccine | Pharmtech Focus

Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 Million Doses of COVID-19 Vaccine

August 5 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today […]

Clinical Trials

 Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial | Pharmtech Focus

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

June 14 2021

Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% […]

COVID-19

 Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility | Pharmtech Focus

Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

May 6 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced […]